Abstract
By the first week of April 2020, more than 1,500,000 positive cases of COVID-19 and more than 50,000 deaths had been officially reported worldwide. While developed countries such as the USA, Italy, England, France, Spain, and Germany struggle to mitigate the propagation of SARS-CoV-2, the COVID-19 pandemic arrived in Latin America, India, and Africa—territories in which the mounted infrastructure for diagnosis is greatly underdeveloped. An actual epidemic emergency does not provide the required timeframe for testing new diagnostic strategies; therefore, the first line of response must be based on commercially and readily available resources. Here, we demonstrate the combined use of a three-dimensional (3D)-printed incubation chamber for commercial Eppendorf PCR tubes, and a colorimetric embodiment of a loop-mediated isothermal amplification (LAMP) reaction scheme for the detection of SARS-CoV-2 nucleic acids. We used this strategy to detect and amplify SARS-CoV-2 DNA sequences using a set of in-house designed initiators that target regions encoding the N protein. We were able to detect and amplify SARS-CoV-2 nucleic acids in the range of ∼625 to 2 × 105 DNA copies by this straightforward method. The accuracy and simplicity of this diagnostics strategy may provide a cost-efficient and reliable alternative for use during the COVID-19 pandemics, particularly in underdeveloped regions were the availability of RT-qPCR instruments may be limited. Moreover, the portability, ease of use, and reproducibility of this strategy make it a reliable alternative for deployment of point-of-care SARS-CoV-2 detection efforts during the pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge funding provided by Consejo Nacional de Tecnología y Ciencias (CONACyT), Mexico.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw data related to the research described in this manuscript has been made available as supplemental material.
